@article{36b80d47634447f7a9adb1b48d113121,
title = "Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus",
abstract = "Interferon lambda 4 protein can be generated in IFNL4-ΔG carriers but not IFNL4-TT homozygotes. We studied 890 anti-hepatitis C virus (HCV)-positive participants in the Women's Interagency HIV Study. Among blacks (n = 555), HCV was more often cleared for those with genotype IFNL4-TT/TT (32.6%; odds ratio [OR], 3.59; P = 3.3 × 10-5) than IFNL4-TT/ΔG (11.3%; OR, 0.95; P =. 86) or IFNL4-ΔG/ΔG (11.9%; referent). Pooling these data with published results in blacks (n = 1678), ORs were 3.84 (P = 8.6 × 10-14) for IFNL4-TT/TT and 1.44 (P =. 03) IFNL4-TT/ΔG, and the area under the curve was 0.64 for IFNL4-ΔG genotype and 0.61 for rs12979860 (IL28B). IFNL4-ΔG is strongly associated with impaired spontaneous HCV clearance.",
keywords = "HCV, IFNL4, IL28B, genetic, viral clearance",
author = "Aka, {Peter V.} and Kuniholm, {Mark H.} and Pfeiffer, {Ruth M.} and Wang, {Alan S.} and Wei Tang and Sabrina Chen and Jacquie Astemborski and Michael Plankey and Villacres, {Maria C.} and Peters, {Marion G.} and Seema Desai and Seaberg, {Eric C.} and Edlin, {Brian R.} and Strickler, {Howard D.} and Thomas, {David L.} and Ludmila Prokunina-Olsson and Sharp, {Gerald B.} and O'Brien, {Thomas R.}",
note = "Funding Information: Financial support. This work was supported by the Intramural Research Program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics). Data in this manuscript were collected by the Women{\textquoteright}s Interagency HIV Study (WIHS) Collaborative Study Group with centers (principal investigators) located at: New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data Analysis Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The WIHS is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI frant UL1 RR024131). The ALIVE cohort is funded by the National Institutes of Drug Abuse DA033541, DA12568, and DA04334 and genetic testing in that cohort by R01013324. The Urban Health Study was funded by National Institutes of Health grants R01-DA09532, R01-DA12109, R01-DA13245 and R01-DA16159 (to B. R. E.); National Cancer Institute contracts N02-CP-91027 and N01-CO-12400 (to B. R. E.); Substance Abuse and Mental Health Services Administration grant H79-TI12103 (to B. R. E.) The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.",
year = "2014",
doi = "10.1093/infdis/jit433",
language = "English (US)",
volume = "209",
pages = "350--354",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",
}